164 related articles for article (PubMed ID: 21466595)
1. Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study.
Guadalix S; Martínez-Díaz-Guerra G; Lora D; Vargas C; Gómez-Juaristi M; Cobaleda B; González EM; Hawkins F
Transpl Int; 2011 Jul; 24(7):657-65. PubMed ID: 21466595
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
4. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
5. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
6. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Van Poznak C; Hannon RA; Mackey JR; Campone M; Apffelstaedt JP; Clack G; Barlow D; Makris A; Eastell R
J Clin Oncol; 2010 Feb; 28(6):967-75. PubMed ID: 20065185
[TBL] [Abstract][Full Text] [Related]
7. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.
Millonig G; Graziadei IW; Eichler D; Pfeiffer KP; Finkenstedt G; Muehllechner P; Koenigsrainer A; Margreiter R; Vogel W
Liver Transpl; 2005 Aug; 11(8):960-6. PubMed ID: 16035083
[TBL] [Abstract][Full Text] [Related]
8. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
[TBL] [Abstract][Full Text] [Related]
10. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
Reid DM; Hughes RA; Laan RF; Sacco-Gibson NA; Wenderoth DH; Adami S; Eusebio RA; Devogelaer JP
J Bone Miner Res; 2000 Jun; 15(6):1006-13. PubMed ID: 10841169
[TBL] [Abstract][Full Text] [Related]
13. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
[TBL] [Abstract][Full Text] [Related]
14. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
[TBL] [Abstract][Full Text] [Related]
15. The relationship between regional bone turnover measured using 18F-fluoride positron emission tomography and changes in BMD is equivalent to that seen for biochemical markers of bone turnover.
Frost ML; Cook GJ; Blake GM; Marsden PK; Fogelman I
J Clin Densitom; 2007; 10(1):46-54. PubMed ID: 17289526
[TBL] [Abstract][Full Text] [Related]
16. Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women.
Tanriverdi HA; Barut A; Sarikaya S
Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):63-8. PubMed ID: 15866088
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
18. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
Reginster JY; Lecart MP; Richy F
J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
Ringe JD; Faber H; Farahmand P; Dorst A
Rheumatol Int; 2006 Mar; 26(5):427-31. PubMed ID: 16001181
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin.
Välimäki MJ; Kinnunen K; Volin L; Tähtelä R; Löyttyniemi E; Laitinen K; Mäkelä P; Keto P; Ruutu T
Bone Marrow Transplant; 1999 Feb; 23(4):355-61. PubMed ID: 10100579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
